TAXOL Rx

Select the drug indication to add to your list

TAXOL

Breast cancer
Gynecologic cancers
Kaposi's sarcoma
Respiratory and thoracic cancers
Only 4 drugs may be compared at once

Generic Name and Formulations:

Paclitaxel 6mg/mL; soln for IV infusion after dilution; contains polyoxyl 35 castor oil, dehydrated alcohol.

Select therapeutic use:

Indications for TAXOL:

Adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. Breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.

Adult:

See full labeling. Premedicate with corticosteroids, diphenhydramine, H2 antagonists. Breast cancer (node-positive): 175mg/m2 IV over 3 hours every 3 weeks for 4 courses administered sequentially to doxorubicin-containing combination chemotherapy. Breast cancer (after failure of initial chemotherapy for metastatic disease or relapse): 175mg/m2 IV over 3 hours every 3 weeks. Hepatic impairment or neutropenia: see full labeling for dose modifications. Do not treat if neutrophil count <1,500cells/mm3 or platelets <100,000cells/mm3.

Children:

Not established.

Contraindications:

Baseline neutrophil count <1,500cells/mm3.

Boxed Warning:

Should be administered under the supervision of an experienced physician. Anaphylaxis and severe hypersensitivity reactions. Bone marrow suppression.

Warnings/Precautions:

Do frequent peripheral blood cell counts. Hepatic dysfunction. Conduction abnormalities: monitor cardiac function. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Pharmacological Class:

Antimicrotubule agent.

Interactions:

May potentiate or be potentiated by CYP2C8 or CYP3A4 substrates, inducers and/or inhibitors. Potentiated by cisplatin. May potentiate doxorubicin.

Adverse Reactions:

Bone marrow suppression (eg, neutropenia, leukopenia, thrombocytopenia, anemia), inj site reactions, infections, hypotension, bradycardia, hypersensitivity reactions (if severe, do not rechallenge), peripheral neuropathy, myalgia, arthralgia, GI upset, mucositis, alopecia, abnormal ECG, elevated liver enzymes.

How Supplied:

Multidose vial (5mL, 16.7mL, 50mL)—1

Indications for TAXOL:

First-line therapy (in combination with cisplatin) and subsequent therapy for advanced carcinoma of the ovary.

Adult:

See full labeling. Premedicate with corticosteroids, diphenhydramine, H2 antagonists. Previously untreated ovarian cancer: 175mg/m2 IV over 3 hours + cisplatin every 3 weeks; or 135mg/m2 IV over 24 hours + cisplatin every 3 weeks. Previously treated ovarian cancer: 135mg/m2 or 175mg/m2 IV over 3 hours every 3 weeks. Hepatic impairment or neutropenia: see full labeling for dose modifications. Do not treat if neutrophil count <1,500cells/mm3 or platelets <100,000cells/mm3.

Children:

Not established.

Contraindications:

Baseline neutrophil count <1,500cells/mm3.

Boxed Warning:

Should be administered under the supervision of an experienced physician. Anaphylaxis and severe hypersensitivity reactions. Bone marrow suppression.

Warnings/Precautions:

Do frequent peripheral blood cell counts. Hepatic dysfunction. Conduction abnormalities: monitor cardiac function. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Pharmacological Class:

Antimicrotubule agent.

Interactions:

May potentiate or be potentiated by CYP2C8 or CYP3A4 substrates, inducers and/or inhibitors. Potentiated by cisplatin. May potentiate doxorubicin.

Adverse Reactions:

Bone marrow suppression (eg, neutropenia, leukopenia, thrombocytopenia, anemia), inj site reactions, infections, hypotension, bradycardia, hypersensitivity reactions (if severe, do not rechallenge), peripheral neuropathy, myalgia, arthralgia, GI upset, mucositis, alopecia, abnormal ECG, elevated liver enzymes.

How Supplied:

Multidose vial (5mL, 16.7mL, 50mL)—1

Indications for TAXOL:

Second-line treatment of AIDS-related Kaposi's sarcoma.

Adult:

See full labeling. Premedicate with corticosteroids, diphenhydramine, H2 antagonists. 135mg/m2 IV over 3 hours every 3 weeks; or 100mg/m2 IV over 3 hours every 2 weeks. Hepatic impairment or neutropenia: see full labeling for dose modifications. Do not treat if neutrophil count <1,000cells/mm3 or platelets <100,000cells/mm3.

Children:

Not established.

Contraindications:

Baseline neutrophil count <1,000cells/mm3.

Boxed Warning:

Should be administered under the supervision of an experienced physician. Anaphylaxis and severe hypersensitivity reactions. Bone marrow suppression.

Warnings/Precautions:

Do frequent peripheral blood cell counts. Hepatic dysfunction. Conduction abnormalities: monitor cardiac function. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Pharmacological Class:

Antimicrotubule agent.

Interactions:

May potentiate or be potentiated by CYP2C8 or CYP3A4 substrates, inducers and/or inhibitors. Potentiated by cisplatin. May potentiate doxorubicin.

Adverse Reactions:

Bone marrow suppression (eg, neutropenia, leukopenia, thrombocytopenia, anemia), inj site reactions, infections, hypotension, bradycardia, hypersensitivity reactions (if severe, do not rechallenge), peripheral neuropathy, myalgia, arthralgia, GI upset, mucositis, alopecia, abnormal ECG, elevated liver enzymes.

How Supplied:

Multidose vial (5mL, 16.7mL, 50mL)—1

Indications for TAXOL:

First-line treatment of non-small cell lung cancer in combination with cisplatin in patients who are not candidates for potentially curative surgery and/or radiation therapy.

Adult:

See full labeling. Premedicate with corticosteroids, diphenhydramine, H2 antagonists. 135mg/m2 IV over 24 hours + cisplatin every 3 weeks. Hepatic impairment or neutropenia: see full labeling for dose modifications. Do not treat if neutrophil count <1,500cells/mm3 or platelets <100,000cells/mm3.

Children:

Not established.

Contraindications:

Baseline neutrophil count <1,500cells/mm3.

Boxed Warning:

Should be administered under the supervision of an experienced physician. Anaphylaxis and severe hypersensitivity reactions. Bone marrow suppression.

Warnings/Precautions:

Do frequent peripheral blood cell counts. Hepatic dysfunction. Conduction abnormalities: monitor cardiac function. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Pharmacological Class:

Antimicrotubule agent.

Interactions:

May potentiate or be potentiated by CYP2C8 or CYP3A4 substrates, inducers and/or inhibitors. Potentiated by cisplatin. May potentiate doxorubicin.

Adverse Reactions:

Bone marrow suppression (eg, neutropenia, leukopenia, thrombocytopenia, anemia), inj site reactions, infections, hypotension, bradycardia, hypersensitivity reactions (if severe, do not rechallenge), peripheral neuropathy, myalgia, arthralgia, GI upset, mucositis, alopecia, abnormal ECG, elevated liver enzymes.

How Supplied:

Multidose vial (5mL, 16.7mL, 50mL)—1